Koers KaloBios Pharmaceuticals Inc Nasdaq
Aandelen
US48344T2096
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- USD | - |
05/01 | 19 behandelingsontwikkelaar Humanigen vraagt faillissement aan bij de rechtbank | RE |
03/01 | Humanigen, Inc. Faillissement aangevraagd | CI |
Omzet 2021 | 3,6 3,32 | Omzet 2022 | 2,51 2,32 | Marktkapitalisatie | 14,29 mln. 13,2 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -237 mln. -219 mln. | Nettowinst (verlies) 2022 | -70 mln. -64,66 mln. | EV/omzet 2021 | 53.517.059 x |
Nettoliquiditeiten 2021 | 45,01 mln. 41,57 mln. | Nettoliquiditeiten 2022 | 10,16 mln. 9,38 mln. | EV/omzet 2022 | 1.644.636 x |
K/w-verhouding 2021 |
-0,92
x | K/w-verhouding 2022 |
-0,15
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 89,65% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07-01-16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07-01-16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06-07-20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 07-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,13% | 89,37 mld. | |
+2,76% | 40,65 mld. | |
-12,32% | 32,81 mld. | |
+52,41% | 25 mld. | |
-17,39% | 15,29 mld. | |
-42,45% | 11,61 mld. | |
-10,48% | 11,49 mld. | |
+6,14% | 8,98 mld. | |
-7,72% | 8,23 mld. |
- Beurs
- Aandelen
- Koers HGENQ
- Koers